Drug intelligence / Profile preview

a3-3a

Development stage: Preclinical
Lead developer: Rush University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

A3-3A is a monoclonal antibody that selectively neutralizes the p40 subunit of the interleukin-12 (IL-12) family. While p40 is a component of the heterodimeric cytokines IL-12 (p40/p35) and IL-23 (p40/p19), research suggests that pancreatic cancer cells produce elevated levels of p40 monomers and p40 homodimers (p402). A3-3A targets these p40 forms to inhibit their role in helping cancer cells escape cell death, thereby promoting apoptosis in pancreatic cancer cells. It was developed for research in the context of the tumor microenvironment and immune evasion in pancreatic adenocarcinoma.

Other names: p40 mAb (a3-3a)anti-p40 monoclonal antibody a3-3aanti-p-40 monoclonal antibody a3-3aanti-p 40 monoclonal antibody a3-3a

Targets

IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on a3-3a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on a3-3a.

Explore the full profile